Home
High Throughput Screening
24 January - 25 January 2005
High Throughput Screening

In recent years pharmaceutical companies have increased research and development spending, however this has failed to generate many new drug approvals. Consequently companies are relying on the ability of screening methods and technologies to identify lead compounds with therapeutic capabilities. However, current screening efforts are proving one of industry’s most potent bottlenecks requiring further attention.

SAE Media Group’s 3rd Annual Advances in High Throughput Screening Conference aims to review and evaluate the latest developments in High Throughput Screening (HTS), with a particular focus on instrumentation, assay methodologies and HTS as a business opportunity. How can HTS systems be integrated into the business? How does a company select the most appropriate technology in the first place? Hear the latest from top pharmaceutical companies as they explain how to adopt the right strategies and right technology for your company. This event will also aim to explore some of the emerging trends in HTS, complete with an outlook on market drivers and shapers and future potential as part of the drug development process.

Gain an insight from key industry leaders in the field including:

Dr Fredric Vinick, Senior Vice President, Drug Discovery, Genzyme
Dr Jefferson Paslay, Vice President, Screening Sciences, Wyeth
Dr Mark Divers, Director, HTS Centre, AstraZeneca
Dr Gregory Kaczorowski, Senior Director, Department of Ion Channels, Merck Research Laboratories
Dr Lorenz Mayr, Technology Programme Head, Lead Discovery Center, Novartis
Dr Andreas Sewing, Head, Automated Screening Technologies, Pfizer
Dr Everard Pap, Head, Assay Technologies, Lead Discovery, Aventis
Dr Emanuel Lohrmann, Research Fellow, HTS, Bayer
Dr Christian Bergsdorf, Post Doctor, Assay Development, HTS, Schering

Programme highlights include:

HTS AS AN INTEGRAL PART OF THE EARLY DRUG DISCOVERY PROCESS: Analyse HTS operations and investments in HTS technologies
INDUSTRIALISATION AND AUTOMATION OF HTS ASSAY DEVELOPMENT: Hear about the bottlenecks of traditional assay development and the impact of automated assays on optimisation
UNMET REQUIREMENTS IN HTS: Explore the areas that utilise the HTS market and the industry responses to market opportunities
LEARN FROM MISTAKES: Investigate the previous HTS methods and the application of new processes
STRATEGIES TO DISCOVER ION CHANNEL DRUGS: Learn about VIPR based ion channels and other novel approaches
INDUSTRY EXPERTS: Network with influential experts from leading pharmaceutical companies and gain an insight into their experiences

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

High Content Screening in drug discovery

  • High content screening assays (functional genomics,
  • protein arrays etc)
  • Screens that provide enhanced biological information at the
  • Sub cellular level
  • Cell-based arrays for high throughput functional analyses
  • Parallel analysis to accelerated discovery and development
  • clock

    10:00

    Increasing the information content generated by HTS through micro-miniaturisation

  • Bionanotechnology and HTS
  • Micro and nano-sensors for HTS cell signals
  • Biological microsystems integration (Lab-on-a-Chip)
  • Surface analysis of functionalised electrodes
  • Biological electron transfer and protein electrochemistry
  • clock

    11:00

    Morning Coffee

    clock

    11:15

    HTS technologies to probe cAMP – dependant cellular events

  • Gaining maximum info from focused libraries
  • Applying single screening data sets to multiple targets
  • Tuning a target screen towards different diseases
  • Developing screens for dual-acting inhibitors
  • Discovery of novel dual acting pde and epac inhibitors
  • clock

    11:45

    Emitted light technologies in high content HTS

  • Advantages of emitted light technologies in HTS
  • Creation of novel light-emitting HTS for discovery of antifungals
  • Application of emitted light in HTS screening of potential new drugs, safety testing and diagnostics.
  • clock

    12:10

    Discussion and questions – review of the session

    clock

    12:30

    Close of Executive Briefing

    clock

    13:30

    Registration & Coffee

    clock

    14:00

    Cell based screening – advantages and disadvantages

  • Understanding the advantages of cell based screening
  • Understanding the disadvantages of the approach
  • User experiences – how effective is cell-based screening in generating validated compound leads
  • Is it more useful in primary or in secondary screens?
  • clock

    14:40

    Infrastructures needed for cell-based screening

  • Automated cell culture
  • Information handling
  • Data analysis
  • clock

    15:10

    Afternoon Tea

    clock

    15:30

    High content vs high throughput screening

  • High content, low throughput, cell based assays?
  • Emerging techniques for higher throughput imaging systems
  • High throughput, low content, cell based assays?
  • clock

    16:00

    Cell pathway screening for key target classes

  • GPCRs
  • Kinases
  • Transcription factors, including nuclear hormone receptors
  • clock

    16:30

    Discussion and questions – review of the session

    clock

    17:00

    Close of Executive Briefing

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Dr Lorenz Mayr

    Dr Lorenz Mayr, Technology Programme Head, Lead Discovery Center, Novartis

    clock

    9:10

    HTS AS AN ITEGRAL PART OF THE EARLY DRUG DISCOVERY PROCESS

    Dr Jefferson Paslay

    Dr Jefferson Paslay, Vice President, Screening Sciences, Wyeth

  • Scaling HTS operations to meet organisational requirements
  • Successful partnerships across the organisation for HTS success
  • Alignment of HTS priorities with discovery goals
  • HTS data deliverables that enable rapid progression of projects
  • Investing in HTS related technologies that add value
  • clock

    9:50

    EXTRACTING VALUE FROM HTS DATA

    Dr Vladimir Dancik

    Dr Vladimir Dancik, Senior Scientist, Millennium Pharmaceuticals

  • Approaches to identify potential false negative hits and eliminate false positive ones
  • Proper selection of activity thresholds
  • Identification of selective and cross-reactive compounds using historical screening data
  • Identification of novel and appealing compounds based on structural information
  • Variability in HTS results as a function of the position of compounds on multiwell plates
  • The impact of these methods on a number of diverse HTS projects
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    PHARMACOLOGY IN µ-VOLUMES

    Dr Emanuel Lohrmann

    Dr Emanuel Lohrmann, Research Fellow, HTS, Bayer

  • Use of functional cell-based assays in uHTS
  • Cell-based technology platform for ion channel uHTS
  • Data processing and analysis
  • ‘In silico’ pharmacology: activating profiling in HTS database for hit evaluation and prioritisation
  • pharmacology: activating profiling in HTS database for hit evaluation and prioritisation
  • Maximise success rates by target portfolio management
  • clock

    11:40

    IMPROVING HIT SELECTION AND LEAD IDENTIFICATION IN HTS

    Dr Stephan Heyse

    Dr Stephan Heyse, Group Leader, Screening Informatics, Genedata

  • Error analysis and rigorous quality control in HTS for obtaining precise activity and potency data
  • Data standardisation and structured data management
  • Advanced algorithms for efficient processing of dose-response data
  • Large-scale cross-assay compound profiling on activity and potency data
  • Joining HTS data with pharmacological profiling data, structural properties and pathway information for efficient identification of high-potential compound clusters
  • Streamlining and automating the analysis workflow for hit selection
  • clock

    12:20

    Networking Lunch

    clock

    13:50

    INDUSTRIALISATION AND AUTOMATION OF HTS ASSAY DEVELOPMENT

    Dr Lorenz Mayr

    Dr Lorenz Mayr, Technology Programme Head, Lead Discovery Center, Novartis

  • Bottlenecks of traditional HTS assay development
  • Impacts of Design-Of-Experiment (DOE) software tools
  • Impact of Automated Assay Optimisation (AAO) hardware tools
  • Novartis' approach to miniaturised and automated HTS assay development and assay optimisation (MAO approach)
  • Case studies from 1536w-automated HTS development/optimisation campaigns
  • Future steps in industrialised and automated HTS assay development
  • clock

    14:30

    LEARNING FROM OUR MISTAKES

    Dr Andreas Sewing

    Dr Andreas Sewing, Head Automated Screening Technologies, Pfizer

  • Corporate compound collections, a historic view
  • Leadlike, druglike? Enriching corporate compound files
  • Success through compound selection
  • HTS and ADME
  • How our processes drive physico-chemical properties
  • clock

    15:10

    Afternoon Tea

    clock

    15:40

    PROFILING PROTEASE FAMILIES

    Dr Chris Luft

    Dr Chris Luft, Senior Scientist, Assay Development, Amphora Discovery

  • Selectivity profiling of human protease inhibitors
  • Scaffold selection based on selectivity, specificity, mechanism and true potency
  • Predictability and repeatability of the protease pipeline
  • Industrialised, highly repeatable process
  • clock

    16:20

    STRATEGIES TO DISCOVER ION CHANNEL DRUGS

    Dr Gregory Kaczorowski

    Dr Gregory Kaczorowski, Senior Director Department of Ion Channels, Merck Research Laboratories

  • Configuring VIPR based ion channel screens with membrane potential dyes
  • Designing and validating HTS for modulators of voltage-gated sodium channels
  • - Potassium channels
  • - Calcium channels
  • - Calcium-activated potassium channels
  • Comparison of VIPR and electrophysiology data
  • Other novel approaches to ion channel medium throughput and high throughput screens
  • clock

    17:00

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Re-registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Bruno Marks

    Bruno Marks, Senior Scientific Officer, ProXara Biotechnology

    clock

    9:10

    THE ROLE OF MINIATURISATION IN A MEDIUM SIZED HTS LAB

    Dr Christian Bergsdorf

    Dr Christian Bergsdorf, Post Doctor, Assay Development & HTS, Schering

  • Presentation of Schering’s miniaturisation approach
  • Data on the implementation of our concept into the different phases of our current HTS processes
  • Compound logistics: storage and automated preparation of 50nl ‘ready-to-use’ compound plates
  • HTS assay runs in miniaturised format: optimisation of current liquid handling equipment, highlighted examples of miniaturised HTS assay formats
  • clock

    9:50

    SCREENING SIGNAL TRANSDUCTION PATHWAYS

    Bob Kendall

    Bob Kendall, Senior Scientist, GE Healthcare

  • Development of a range of integrated tools for target validation
  • Instrument, biology and image analysis
  • Whole system imaging: model systems
  • Optical imaging from cells to whole organisms
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    NEW CHALLANGES FOR BIG PHARMA

    Kevin Hrusovsky

    Kevin Hrusovsky, Chief Executive Officer, Caliper Life Sciences

  • The industry paradox: more research and development spending, more technology, more compounds screened….less success
  • High throughput vs high output: the goal of screeners is changing
  • The role of ‘organisational learning’ a more hostilic approach to drug discovery
  • Minimising a late-stage and clinical failures through early detection and prevention
  • clock

    11:40

    DRUG DISCOVERY IN THE AGE OF COMPLEX BIOLOGY

  • Discovering drugs for diseases which lack any good therapy is very difficult
  • Often, the biology is complex and our understanding of the cause of the disease is inadequate
  • Nonetheless, we can and should work toward finding cures for high unmet medical need diseases
  • Many approaches can work but disease-related biology is essential for success
  • Fredric Vinick

    Fredric Vinick, Senior Vice President of Drug Discovery & Developmet, Genzyme Genetics

    clock

    12:10

    Networking Lunch

    clock

    13:40

    ANTIBODIES IN CELLULAR SYSTEMS AND HTS

    Dr Stephen Clulow

    Dr Stephen Clulow, Director, Lead-Discovery, Cambridge Antibody Technology

  • Effective screening cascades for antibody drugs
  • Antibody format and expression system influence assay results
  • How the target and screening cascade influence antibody leads
  • What’s really important for antibody drugs: solving the epitope, affinity, avidity, potency puzzle
  • clock

    14:20

    INCREASING FLEXIBILITY

    Dr Mark Divers

    Dr Mark Divers, Director, HTS Centre, AstraZeneca

  • Is HTS delivering
  • Building an integrated HTS function
  • Effective application of HTS
  • Is file screening always the best way?
  • Maintaining, exploiting and improving the compound bank
  • clock

    15:00

    Afternoon Tea

    clock

    15:20

    THE POST-SCREENING BOTTLENECK

    Dr Everard Pap

    Dr Everard Pap, Head Assay, Technologies, Lead Discovery, Aventis

  • The nomination after HTS of a compound series for hit status
  • Prioritisation of thousands of screening activities
  • Experiments on assays through the early decision-making process
  • Added value compounds
  • Analysis on post-screening bottlenecks
  • clock

    16:00

    THE SUCESSFUL FUNCTION OF HTS

    Dr Christian Apfel

    Dr Christian Apfel, Head Assay Development & HTS, F Hoffman - La Roche

  • Development and installation of a uHTS system
  • New bottlenecks in the drug discovery process
  • Efficient assay development and tool generation
  • Demand for rapid hit confirmation and compound logistics
  • Quick analysis of large amounts of dose response data
  • clock

    16:40

    Chairperson’s Closing Remarks and Close of Conference

    Bruno Marks

    Bruno Marks, Senior Scientific Officer, ProXara Biotechnology

    Workshops

    High-Content Screening

    High-Content Screening

    Jurys Great Russell Street Hotel
    26 January 2005
    London, United Kingdom

    Cell Pathways

    Cell Pathways

    Jurys Great Russell Street Hotel
    26 January 2005
    London, United Kingdom

    Jurys Great Russell Street Hotel

    16-22 Great Russell Street
    London WC1B 3NN
    United Kingdom

    Jurys Great Russell Street Hotel

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.